# Hovione to ramp up output of Ligand's Captisol for COVID-19 treatment

Hovione has signed an agreement to significantly increase production of Ligand Pharmaceuticals' Captisol excipient, used in Gilead's remdesivir COVID-19 treatment, with monthly output soon matching previous annual production.

- Type: Contract
- Announced: 2020-09-28
- Status: announced
- Capacity: per month the quantity it usually produces in one year
- Products: Captisol (chemically modified cyclodextrin excipient), remdesivir
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Hovione](https://endata.com/companies/23243.md) (supplier)
- [Ligand Pharmaceuticals](https://endata.com/companies/50186.md) (customer)
- [Gilead Sciences](https://endata.com/companies/50187.md) (partner)

## Sources

- [doi.org](https://doi.org/10.1021/cen-09837-buscon13), 2020-09-28: "Hovione will soon be producing per month the quantity it usually produces in one year."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.